About Apnar Pharma
Apnar Pharma is a Healthcare company based in Chino (United States) founded in 2014. It produces high-quality pharmaceutical products including tablets, capsules, syrups, and injectables. It operates on a B2B model. The company has 95 employees. Apnar Pharma has completed 1 acquisition, including Aurex Laboratories. Its Indian entity Apnar Pharma Private Limited reported revenue of ₹14.22 Cr. Its focus areas include Pharmaceuticals, Manufacturing and Drug Production.
Company details
Apnar Pharma operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug production. Produces high-quality pharmaceutical products including tablets, capsules, syrups, and injectables. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters Chino, United States
- Employees 95
- SectorsHealthcare
- Website apnarpharma.com
- Legal Name Apnar Pharma Private Limited
- Date of Incorporation 12 Dec, 2014
- Jurisdiction Padra, Gujarat, India
- Indian entity revenue₹14.22 Cr
FY 2025 · -48% YoY
- Indian entity net loss-₹68.7 Lakh
FY 2025 · -5% margin
- Indian entity EBITDA₹4.24 Cr
FY 2025 · 30% margin
- Employee Count95
- Investments & Acquisitions
Associated legal entities of Apnar Pharma
Apnar Pharma operates through Apnar Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Apnar Pharma Private Limited CIN U73100GJ2014PTC081520 | Active | 12 Dec 2014 | Padra, Gujarat | ₹14.2 Cr | 95 | 3 | View details |
Board of directors of Apnar Pharma Private Limited (Apnar Pharma)
Apnar Pharma Private Limited is the primary company behind Apnar Pharma. The board of Apnar Pharma Private Limited currently have 3 directors; the longest-serving is Swapnil Kantibhai Patel, appointed in 2014. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Swapnil Kantibhai Patel DIN 06952743 | Director | 12 Dec 2014 | 11 yrs 10 mo | Apnar Pharma Private Limited |
| Dharmesh Bhikhabhai Patel DIN 07022276 | Director | 24 Jan 2015 | 11 yrs 8 mo | Apnar Pharma Private Limited |
| Umesh Patel DIN 07094819 | Director | 25 Feb 2015 | 11 yrs 7 mo | Apnar Pharma Private Limited |
Financials of Apnar Pharma
Figures of Apnar Pharma Private Limited, the primary company behind Apnar Pharma, for FY 2025. Revenue was ₹14.22 Cr (-48% year on year). Net loss was -₹68.7 Lakh (-5% margin). EBITDA was ₹4.24 Cr (30% margin). Revenue has grown at a compounded annual rate of -2% over three years and +21% over five years.
- ₹14.22 CrRevenue · FY 2025 · -48% YoY
- -₹68.7 LakhNet loss · -5% margin
- ₹4.24 CrEBITDA · 30% margin
- ₹7.55 CrPaid-up capital
- 95Employees (provident fund records)
- -2%Revenue CAGR, 3 years
- +21%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Apnar Pharma Private Limited are on its company page.
Detailed financial statements for Apnar Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apnar Pharma
Apnar Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aurex Laboratories.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drug manufacturing for multiple therapeutic areas is conducted through R&D. | aurexlabs.com | Windsor, Canada | 2014 | Feb 2022 | •••• |
Complete acquisition details for Apnar Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Apnar Pharma
2 dated milestones of Apnar Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Apnar Pharma is founded.
- Acquisition Acquires Aurex Laboratories.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Apnar Pharma (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apnar Pharma
Complete news archive for Apnar Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apnar Pharma
Apnar Pharma was founded in 2014.
Apnar Pharma is headquartered in Chino, United States. It is registered at Chino, California, United States.
Apnar Pharma has 95 employees.
The primary company behind Apnar Pharma, Apnar Pharma Private Limited, reported revenue of ₹14.22 Cr for FY 2025, down 48% year on year.
Apnar Pharma operates with a B2B model, focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug production. Produces high-quality pharmaceutical products including tablets, capsules, syrups, and injectables. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Apnar Pharma has made 1 acquisition, including Aurex Laboratories.
Apnar Pharma operates through Apnar Pharma Private Limited.
The legal entities of Apnar Pharma currently have 3 directors, including Umesh Patel, Dharmesh Bhikhabhai Patel, Swapnil Kantibhai Patel.